Literature DB >> 11369291

Monoclonal antibody strategies to block angiogenesis.

D J. Hicklin1, L Witte, Z Zhu, F Liao, Y Wu, Y Li, P Bohlen.   

Abstract

Antibodies represent a unique class of therapeutics because of their high specificity towards a defined target antigen. Recent clinical success with antibody-based cancer therapeutics has led to an increase in the clinical development of these agents. Antibody therapeutics offer a promising approach for inhibiting new blood vessel formation (angiogenesis), which is associated with a variety of diseases, including cancer. In this review we will focus on angiogenesis-related mechanisms targeted by antibody-based therapeutics, with an emphasis on those studies where pre-clinical in vivo data is available.

Entities:  

Year:  2001        PMID： 11369291     DOI： 10.1016/s1359-6446(01)01759-7

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  8 in total

Review 1.  The impact of anti-angiogenic agents on cancer therapy.

Authors:  Dieter Marmé
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-16       Impact factor: 4.553

2.  Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment.

Authors:  Yoon-Jin Lee; Daniel L Karl; Ugwuji N Maduekwe; Courtney Rothrock; Sandra Ryeom; Patricia A D'Amore; Sam S Yoon
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

3.  Novel short peptides isolated from phage display library inhibit vascular endothelial growth factor activity.

Authors:  Berrin Erdag; Koray B Balcioglu; Asli Kumbasar; Omur Celikbicak; Gabrielle Zeder-Lutz; Danièle Altschuh; Bekir Salih; Kemal Baysal
Journal:  Mol Biotechnol       Date:  2007-01       Impact factor: 2.695

4.  Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.

Authors:  Linda T Vahdat; Rachel Layman; Denise A Yardley; William Gradishar; Mohamad A Salkeni; Anil Joy; Agustin A Garcia; Patrick Ward; James Khatcheressian; Joseph Sparano; Gladys Rodriguez; Shande Tang; Ling Gao; Rita P Dalal; John Kauh; Kathy Miller
Journal:  Oncologist       Date:  2017-02-20

Review 5.  Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with 90Y or 177Lu.

Authors:  Urszula Karczmarczyk; Agnieszka Sawicka; Piotr Garnuszek; Michał Maurin; Wioletta Wojdowska
Journal:  J Med Chem       Date:  2022-04-20       Impact factor: 8.039

6.  Cytotoxic Effect of Immunotoxin Containing The Truncated Form of Pseudomonas Exotoxin A and Anti-VEGFR2 on HUVEC and MCF-7 Cell Lines.

Authors:  Elahe Safari; Ahmad Zavaran Hosseini; Zuhair Hassan; Khosro Khajeh; Mehdi Shafiee Ardestani; Behzad Baradaran
Journal:  Cell J       Date:  2014-05-25       Impact factor: 2.479

7.  A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer.

Authors:  D Ross Camidge; Eamon M Berge; Robert C Doebele; Marc S Ballas; Thierry Jahan; Missak Haigentz; David Hoffman; James Spicer; Howard West; Pablo Lee; Ling Yang; Adarsh Joshi; Ling Gao; Sergey Yurasov; Alain Mita
Journal:  J Thorac Oncol       Date:  2014-10       Impact factor: 15.609

8.  Proteomic Analysis Shows Constitutive Secretion of MIF and p53-associated Activity of COX-2-/- Lung Fibroblasts.

Authors:  Mandar Dave; Abul B M M K Islam; Roderick V Jensen; Agueda Rostagno; Jorge Ghiso; Ashok R Amin
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-12-13       Impact factor: 7.691
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.